Vir Biotechnology, Inc. [VIR] - Vir Biotechnology appoints Aziz Sawaf as CFO
Effective October 5, 2026, Aziz Sawaf has been appointed as Executive Vice President and Chief Financial Officer of Vir Biotechnology, succeeding Brent Sabatini, who will remain as Senior Vice President and Chief Accounting Officer.
Why this matters
Vir Biotechnology, Inc., incorporated in Delaware, operates in the biological products industry, focusing on developing innovative treatments for infectious diseases. The company has announced the appointment of Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective October 5, 2026. This change follows Brent Sabatini's tenure as interim principal financial officer; Sabatini will continue as Senior Vice President and Chief Accounting Officer. Sawaf joins Vir from Theravance Biopharma, where he served as CFO and Senior Vice President of Operations Strategy, bringing extensive experience from his previous roles at Theravance and Gilead Sciences. Sawaf's compensation package includes an annualized base salary of $520,000, eligibility for a 45% target bonus, and a one-time cash sign-on bonus totaling $150,000.